项目实施主体及地点曾有调整，其中"6000吨高纯氟化锂"相关建设已调整至全资子公司江西天际新能源科技有限公司实施，实施 地点新增江西省九江市瑞昌市。截至2025年11月30日，该项目已累计投入募集资金6.98亿元，投资进度达79.66%；尚未使用的募 集资金为1.86亿元（含利息、现金管理收益扣除手续费净额），其中1.75亿元用于暂时补充流动资金，剩余1111.78万元存放于募 集资金专用账户。 对于本次延期，天际股份表示，公司结合客户需求、市场环境和发展规划进行了审慎评估，为保障项目建设质量与预期效果，实 现资源合理高效配置，对项目建设实施动态控制，在满足当前生产需求的基础上，合理控制产能扩张和募集资金使用节奏，导致 实际投资进度与原计划存在差异。 12月12日，天际股份发布公告，公司审议通过《关于募投项目延期的议案》。在不改变项目实施主体、建设内容、募集资金用途 及投资规模的前提下，公司将"3万吨六氟磷酸锂、6000吨高纯氟化锂等新型电解质锂盐及一体化配套项目"的预定可使用状态日 期从2025年12月延期至2026年12月。 据悉，天际股份此前经中国证券监督管理委员会核准，向特定对象发行股票募集资金总额约 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001373 证券简称：翔腾新材 公告编号：2025-056 江苏翔腾新材料股份有限公司 为全面贯彻落实最新法律、法规及规范性文件要求，进一步提升公司治理水平，根据《公司法》《上市 公司章程指引（2025年修订）》等法律法规、规范性文件的规定，结合公司发展的实际情况，公司对 《公司章程》进行了全面的梳理和修订，具体修订内容对照如下： ■ 一、取消监事会的情况 根据《中华人民共和国公司法（2023年修订）》（以下简称"《公司法》"）、中国证券监督管理委员会 《关于新〈公司法〉配套制度规则实施相关过渡期安排》及《上市公司章程指引（2025年修订）》等有 关规定，公司将不再设置监事会及监事，监事会相关职权由董事会审计委员会行使，公司《监事会议事 规则》等监事会相关制度相应废止，公司各项制度中涉及监事会、监事的规定不再适用。 在公司股东大会审议通过取消监事会事项前，公司第二届监事会仍将继续严格遵守《公司法》《中华人 民共和国证券法》等法律法规和规范性文件的要求勤勉履职。 二、《公司章程》的修订情况 关于修订《公司章程》并办理工商变更登记 及修订和制定部分治理 ...

Core Viewpoint - Longbai Group aims to become a global leader in titanium-based materials, focusing on innovation and sustainable growth while expanding its market presence globally [1][5]. Group 1: Business Strategy and Growth - Longbai Group has transitioned from a struggling local enterprise to a leading company in the titanium industry, driven by innovation and a dual strategy of internal growth and external expansion [1][4]. - The company has established a global leading production capacity with an annual output of 1.51 million tons of titanium dioxide and 80,000 tons of sponge titanium, both ranking first globally [2][3]. - Longbai Group has shifted its focus to titanium dioxide, abandoning the development of aluminum sulfate and slowing down the growth of zirconium salt to concentrate resources on this area [2]. Group 2: Innovation and Technology - The company has innovated its production processes by introducing large-scale bubbling chlorination technology for titanium dioxide, achieving full control over core intellectual property [2][3]. - Longbai Group invests over 1 billion yuan annually in research and development, emphasizing the importance of innovation for future growth [3]. Group 3: Mergers and Acquisitions - The company has successfully expanded its operations through strategic acquisitions, including the purchase of Yunnan Metallurgical New Li and Panzhihua Fengyuan Mining, significantly increasing its sponge titanium production capacity [3][4]. - Future acquisitions will focus on core technologies and key resource elements, with an emphasis on overseas opportunities [4]. Group 4: Global Expansion - Longbai Group is accelerating its globalization efforts, with products currently available in over 110 countries and regions [5]. - The company is exploring resource acquisition in Australia and potential production facilities in Southeast Asia and Central Asia to extend its production capacity internationally [5].

Core Viewpoint - The company, Yunnan Lincang Xin Yuan Germanium Co., Ltd., has approved the establishment of a holding subsidiary, Yunnan Germanium Biotechnology Co., Ltd., through a joint investment of 10 million RMB with Kunming Haliwa Enterprise Management Partnership, focusing on the development of daily chemical products and other applications related to organic germanium [5][20]. Group 1: Investment Overview - The board of directors approved the investment to establish a holding subsidiary with a total capital of 10 million RMB, where the company will contribute 7 million RMB and Kunming Haliwa will contribute 3 million RMB [5][20]. - The new subsidiary will primarily engage in the development of daily chemical products centered around organic germanium [5][20]. Group 2: Subsidiary Details - The proposed subsidiary, Yunnan Germanium Biotechnology Co., Ltd., will have a registered capital of 10 million RMB and will be located in the Kunming High-tech Industrial Development Zone [8][9]. - The business scope of the subsidiary includes research and application of cell technology, production and sales of daily chemical products, and health consulting services, among others [8][9]. Group 3: Investment Purpose and Impact - The investment aims to cultivate a business segment with sustainable growth potential, extending the company's main business downstream and enhancing its industrial chain layout [20]. - The funding for this investment will come entirely from the company's own funds, ensuring that normal operations and financial stability are maintained [20].

Core Viewpoint - Wanhua Chemical executed a block trade on December 12, with a volume of 42,800 shares and a transaction value of 2.9305 million yuan, at a price of 68.47 yuan per share, indicating stable trading activity in the stock [1] Trading Activity - The block trade involved a total of 42,800 shares with a transaction amount of 2.9305 million yuan, executed at a price of 68.47 yuan, which was the same as the closing price for the day, resulting in a 0% premium [1] - The buyer was Guotai Junan Securities Co., Ltd. headquarters, while the seller was an institutional proprietary account [1] Market Performance - On the same day, Wanhua Chemical's closing price was 68.47 yuan, with a turnover rate of 0.72% and a total trading volume of 1.533 billion yuan [1] - The stock experienced a net outflow of 50.4234 million yuan in main funds for the day, and it has seen a cumulative decline of 2.16% over the past five days, with a total net outflow of 566 million yuan [1] Margin Trading Data - The latest margin financing balance for Wanhua Chemical is 2.873 billion yuan, which has increased by 13.1456 million yuan over the past five days, reflecting a growth rate of 0.46% [1] Institutional Ratings - In the past five days, one institution has provided a rating for the stock, with Huatai Securities setting the highest target price at 85.20 yuan as of December 8 [1]

截至发稿，博源化工市值为254亿元。 每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 （记者 曾健辉） 每经AI快讯，博源化工（SZ 000683，收盘价：6.84元）12月12日晚间发布公告称，公司九届三十六次 董事会会议于2025年12月12日在鄂尔多斯市东胜区鄂托克西街博源大厦19层会议室以现场和视频相结合 的方式召开。会议审议了《关于2023年限制性股票激励计划首次授予部分第二个解除限售期解除限售条 件成就的议案》等文件。 2025年1至6月份，博源化工的营业收入构成为：纯碱和小苏打占比72.89%，尿素占比25.08%，非金属 矿采选业占比1.56%，其他业务占比0.46%。 ...

Group 1 - The core viewpoint of the article is that Luxi Chemical has raised the ex-factory price of dichloromethane by 20 yuan/ton to 1730 yuan/ton, indicating a tightening market supply or increased demand, which directly supports spot prices [1][4] - The price adjustment reflects the company's willingness to maintain prices, and it is expected that the spot market may continue to rise in the short term, although attention should be paid to downstream acceptance and overall industry supply-demand changes [2][5] - The pricing mechanism mentioned is based on big data and a pricing model from the Business Society, which serves as a trading guide price, applicable for determining settlement prices for specified dates or average prices over specified periods [2][5] Group 2 - The adjustment coefficient (K) in the pricing formula includes factors such as account period costs [3][6] - The premium and discount (C) in the pricing formula account for logistics costs, brand price differences, and regional price differences [3][6]

Core Viewpoint - The company has approved a project to establish an annual production capacity of 2,000 tons of specialty high-performance polymer PEEK and key intermediate 4,4′-difluorobenzophenone, with a total investment of 193.25 million yuan [1] Investment Details - Total investment for the project amounts to 193.25 million yuan, which includes 84.25 million yuan for equipment and installation, 79 million yuan for construction, and 30 million yuan for working capital [1] Strategic Implications - The project enables the company to enter the high-performance engineering plastics market, breaking the long-standing monopoly of international giants in this sector [1] - The production of 4,4′-difluorobenzophenone (DFBP) will create a closed-loop industrial chain from intermediate to PEEK finished products, aligning with national policies supporting new materials and enhancing the company's strategic position in high-end manufacturing [1]

格隆汇12月12日丨大洋生物(003017.SZ)公布，为了贯彻公司主导产品发展战略，合理布局碳酸钾产 能，进一步丰富碳酸钾品类，提升市场供给能力，贴近市场，方便售后服务，优化行业资源配置，不断 提升公司在行业中的竞争力。公司拟与山东亚荣化学股份有限公司签署《氢氧化钾产品供需战略合作协 议》，拟通过全资子公司分期建设年产6万吨氢氧化钾碳化法轻质碳酸钾和3万吨流化床法重质碳酸钾等 新材料项目，利用山东亚荣化学股份有限公司氢氧化钾产业贯通以及园区二氧化碳稳定供应的配套优 势，扩充碳酸钾产品生产产能。同时，整合地方资源，加强园区上下游产业协同，为未来增量品种准备 发展空间。项目拟投资5亿元（最终投资总额以实际投资为准）。公司拟在山东宁阳化工产业园设立全 资子公司山东大洋新材料有限公司（暂定名，最终以工商行政管理部门核准登记为准；以下又称"项目 公司"），由其作为本次项目的投资主体。 ...

Core Viewpoint - The company has approved a project to establish an annual production capacity of 2,000 tons of specialty polymer material PEEK and key intermediate 4,4′-difluorobenzophenone, with a total investment of 193.25 million yuan [1] Investment Details - Total investment for the project is 193.25 million yuan, which includes 84.25 million yuan for equipment and installation, 79 million yuan for construction, and 30 million yuan for working capital [1] Strategic Implications - The project enables the company to enter the high-performance engineering plastics market, breaking the long-standing monopoly of international giants in this sector [1] - The production of 4,4′-difluorobenzophenone (DFBP) will create a closed-loop industrial chain from intermediate to PEEK finished products, aligning with national policies supporting new materials and enhancing the company's strategic position in high-end manufacturing [1]